Drug Profile
Research programme: antibody drug conjugates - Oxford BioTherapeutics
Alternative Names: NMS-P945; OX001L ADC; OX001L antibody-drug conjugateLatest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Oxford BioTherapeutics
- Class 3-ring heterocyclic compounds; Antineoplastics; Immunoconjugates; Indoles; Thiophenes
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 20 Sep 2023 Pharmacodynamics data from a preclinical trial in Cancer released by Nerviano Medical Sciences
- 28 May 2022 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral)
- 21 Apr 2018 Preclinical trials in Cancer in United Kingdom (Parenteral) before April 2018